Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or ...

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or ...

New York, New York--(Newsfile Corp. - January 22, 2026) - Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of LifeMD, Inc. (NASDAQ: LFMD)  breached their fiduciary duties to shareholders. According to a federal securities lawsuit, Insiders at LifeMD caused the company to misrepresent or fail to disclose that: (1) LifeMD's competitive position was materially overstated; (2) raising LifeMD's 2025 guidance was reckless because rising customer acquisit ...

Group 1: Market Activity - Several biotech and healthcare companies experienced notable gains in after-hours trading, indicating renewed investor interest in drug development and healthcare services [1] - Zentalis Pharmaceuticals, Inc. (ZNTL) surged 17.65% to close at $4.40, attributed to a recent corporate update that boosted investor confidence in its azenosertib development program [2] - LifeMD, Inc. (LFMD) climbed 12.18% to $4.33 following the announcement of a new senior secured revolving credit facility with Citizens Bank, providing up to $50 million in total availability [3] Group 2: Company-Specific Developments - NanoViricides, Inc. (NNVC) advanced 11.11% to $1.24, driven by speculative interest despite no recent news [4] - Intelligent Bio Solutions Inc. (INBS) posted a 9.10% increase, closing at $19.55, continuing to gain momentum from overall investor enthusiasm in the biotech sector [4] - IO Biotech, Inc. (IOBT) rose 6.49% to $0.60, suggesting bargain-hunting activity at lower price levels [5] Group 3: Financing and Agreements - China SXT Pharmaceuticals, Inc. (SXTC) advanced 2.06% to $18.29 after disclosing a definitive agreement for the purchase of 66,666,666 Class A ordinary shares at $0.15 per share, highlighting efforts to strengthen its capital position [6]

Core Viewpoint - LifeMD, Inc. has successfully closed a new senior secured revolving credit facility with Citizens Bank, providing up to $50 million in total availability to support its growth initiatives and enhance financial flexibility [1][2]. Financial Details - The revolving credit facility has a maturity date of January 2, 2029, with $30 million of committed availability and an accordion option of up to $20 million [1]. - As of the closing date, LifeMD has not drawn any balance on the facility, indicating sufficient cash on hand and expected cash flow for its organic growth [1]. - The loans under the facility will bear interest based on either Term SOFR plus a spread of 150 to 225 basis points or the Alternate Base Rate plus a spread of 50 to 125 basis points [3]. - Fees on the committed unused portion of the facility range from 0.225% to 0.30%, depending on leverage, and there is no upfront fee for LifeMD [3]. Company Overview - LifeMD is a leading provider of virtual primary care and pharmacy services, offering telemedicine and access to laboratory and pharmacy services across more than 200 conditions [4]. - The company utilizes a vertically integrated digital care platform, a 50-state affiliated medical group, and a state-of-the-art compounding pharmacy to enhance access to high-quality and affordable care [4].

Group 1: Fox and Flutter's FanDuel - Fox has the option to acquire an 18.6% stake in Flutter's FanDuel, which holds over 30% market share in U.S. sports betting [2][3] - The option originated from Fox's 2019 investment in The Stars Group, which was later folded into FanDuel after Flutter's acquisition [3] - CEO Lachlan Murdoch confirmed Fox's intention to exercise the option, with a potential FanDuel valuation around $35 billion [4] Group 2: Market Reactions and Other News - Analysts view the FanDuel option as a hidden asset value for Fox, with varying opinions on the timing for exercising the option [5] - LifeMD and GoodRx stocks rose after adding Novo Nordisk's Wegovy weight-loss pill to their offerings, priced at $149 per month [5] - Samsung and SK hynix are expected to raise server memory prices by up to 70% in Q1 due to increased AI demand [6]

Shares of LifeMD (LFMD) and GoodRx (GDRX) traded higher in the premarket on Monday after the companies announced the availability of Novo Nordisk’s (NVO) Wegovy pill as part of their product offerings. The announcements came shortly after the Danish drugmaker ...

Core Viewpoint - LifeMD, Inc. has expanded its virtual weight management offerings by introducing Novo Nordisk's Wegovy pill, the first FDA-approved oral GLP-1 therapy for chronic weight management and cardiovascular health, available for eligible patients at a starting price of $149 per month [1][5]. Group 1: Product Offering - LifeMD is now offering Wegovy (semaglutide) through its telehealth platform, enhancing access to affordable branded treatment options for weight management [1]. - Wegovy is indicated for reducing excess body weight, supporting long-term weight maintenance, and lowering the risk of major adverse cardiovascular events, with a Phase 3 trial showing a mean weight loss of 16.6% compared to 2.7% with placebo [3]. - The oral formulation of Wegovy is expected to attract patients who are hesitant to use injectable treatments, thereby broadening access to GLP-1 therapies [3]. Group 2: Collaboration and Integration - LifeMD's collaboration with Novo Nordisk is highlighted, with LifeMD being featured as a trusted telehealth provider on NovoCare and Wegovy websites, reflecting the demand for convenient access to GLP-1 therapies [2]. - The integration with NovoCare Pharmacy allows streamlined access to both injectable and oral GLP-1 medications, including Wegovy and Ozempic, at competitive cash-pay pricing [4]. - LifeMD provides a comprehensive experience that includes virtual visits, ongoing clinical oversight, diagnostic testing, pharmacy fulfillment, and simplified billing [4]. Group 3: Pricing and Availability - Wegovy 1.5mg and 4mg pills are available for $149 per month, with future pricing adjustments planned for April 15, 2026, where 4mg will be priced at $199 and higher doses at $299 per month [5].

Core Insights - Biotech companies experienced significant gains in after-hours trading, driven by investor interest despite limited news catalysts [1] Company Updates - GH Research PLC (GHRS) saw the largest increase, rising 22.36% to $16.20 ahead of a key update on its Investigational New Drug Application (IND) for GH001 with the FDA, scheduled for January 5, 2026 [2] - Phathom Pharmaceuticals, Inc. (PHAT) increased by 5.03% to $16.50, with the rise attributed to investor positioning rather than new announcements [3] - Forte Biosciences, Inc. (FBRX) gained 3.56%, closing at $24.45, continuing its upward trend in the biotech sector without any new updates [3] - OKYO Pharma Limited (OKYO) advanced 5.38% to $2.35, influenced by prior disclosures regarding share acquisitions by its Executive Chairman [4] - Zai Lab Limited (ZLAB) rose 5.60% to $18.30, reflecting ongoing investor interest in international biotech firms [5] - LifeMD, Inc. (LFMD) added 3.15% to $3.60, with no corporate updates released [5] - Werewolf Therapeutics, Inc. (HOWL) climbed 3.58% to $0.67, indicating speculative interest in smaller-cap biotech stocks [6] - Corvus Pharmaceuticals, Inc. (CRVS) increased by 7.24% to $7.85, extending its upward momentum without any new announcements [6]

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...